Clinical Effectiveness of CEM in Diagnosis of Additional Findings at Preoperative Breast Magnetic Resonance Imaging

NANot yet recruitingINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Breast Cancer
Interventions
DIAGNOSTIC_TEST

contrast-enhanced spectral mammography

"After enrollment, subjects should undergo contrast-enhanced spectral mammography again within within 28 days of MRI examination.~Iopromide/contrast agent is intravenously administered two minutes prior to the first (dual-energy) image acquisition.~* The dosage of iodine contrast agent is calculated as 1.5 mL/kg of iopromide 370 mgI/ml.~* Injecting with high pressure syringe (Stellant, Bayer AG) at an IDR of 3ml/s, followed by 10 ml normal saline."

Trial Locations (1)

430000

Union Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

NCT06475066 - Clinical Effectiveness of CEM in Diagnosis of Additional Findings at Preoperative Breast Magnetic Resonance Imaging | Biotech Hunter | Biotech Hunter